trending Market Intelligence /marketintelligence/en/news-insights/trending/Mjm1GR6Hk0BWFrfdALuDmg2 content esgSubNav
In This List

US FDA grants orphan status to OncoSec's cancer drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US FDA grants orphan status to OncoSec's cancer drug

The U.S. Food and Drug Administration granted an orphan drug designation to OncoSec Medical Inc.'s pIL-12, known as tavokinogene telsaplasmid, for the treatment of unresectable metastatic melanoma.

Tavokinogene telsaplasmid is the active biologic agent in ImmunoPulse IL-12, the company's lead product candidate.

OncoSec said the designation will provide the company with eligibility for certain development incentives, including tax credits for clinical testing, exemption from a prescription drug user fee, and seven years of market exclusivity.

The company is starting a phase 2 trial of the product in combination with Keytruda in patients with metastatic melanoma following disease progression on previous treatment with an anti-PD-1 therapy.